

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6541747

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
FORMA THERAPEUTICS, INC.	11/06/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	FORMA TM2, INC.
<b>Street Address:</b>	500 ARSENAL STREET
<b>Internal Address:</b>	SUITE 100
<b>City:</b>	WATERTOWN
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02472
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17101018
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)502-5002
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	617-248-5000
<b>Email:</b>	PatentDocket@choate.com
<b>Correspondent Name:</b>	CHOATE HALL & STEWART LLP-PATENT DOCKET
<b>Address Line 1:</b>	TWO INTERNATIONAL PLACE
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02110
<b>ATTORNEY DOCKET NUMBER:</b>	2012552-1163
<b>NAME OF SUBMITTER:</b>	ERICA M. D'AMATO
<b>SIGNATURE:</b>	/Erica M. D'Amato/
<b>DATE SIGNED:</b>	02/09/2021
<b>Total Attachments: 4</b>	
source=Assignment (FTI to FTM2)#page1.tif	
source=Assignment (FTI to FTM2)#page2.tif	
source=Assignment (FTI to FTM2)#page3.tif	
source=Assignment (FTI to FTM2)#page4.tif	

## CONFIRMATION OF PATENT ASSIGNMENT

This Confirmation of Patent Assignment is entered into by and between **FORMA THERAPEUTICS, INC.**, a Delaware corporation having a place of business at 500 Arsenal St., Suite 100, Watertown, Massachusetts 02472 ("FTI"), and **FORMA TM2, INC.**, a Delaware corporation having a place of business at 500 Arsenal St., Suite 100, Watertown, Massachusetts 02472 ("FTM2").

**WHEREAS**, FTI has an interest in the patent applications and patents listed on Schedule A, attached hereto and a part of this agreement (collectively, the "Patents"), by virtue of assignment from at least one inventor;

**WHEREAS**, FTI, FTM2, and Forma Therapeutics Holdings, LLC, a Delaware limited liability company ("FTH"), entered into a Contribution Agreement effective December 8, 2016 (the "Contribution Agreement");

**WHEREAS**, pursuant to Section 2.1.1 of the Contribution Agreement, FTI, FTM2, and FTH agreed that the whole right, title, and interest in and to the Patents would be sold, conveyed, transferred, assigned, and delivered by FTI to FTM2; and

**WHEREAS**, FTI, FTM2, and FTH wish to confirm that FTI has sold, conveyed, transferred, assigned, and delivered and/or does hereby sell, convey, transfer, assign, and deliver to FTM2, FTI's whole right, title, and interest in and to the Patents.

**NOW THEREFORE**, pursuant to such Contribution Agreement and in consideration of the terms set forth therein, FTI hereby confirms that it has sold, conveyed, transferred, assigned, and delivered and does hereby sell, convey, transfer, assign, and deliver to FTM2, FTI's whole right, title, and interest, free from all encumbrances, in and throughout the United States of America, its territories, and all foreign countries, in and to the Patents, including any right of priority thereto. This Confirmation of Patent Assignment applies i) to the Patents, ii) to any patent application that is based in whole or in part on the Patents, including any divisional, continuing, substitute, renewal, reissue, reexamination, and other patent application(s), including any patent application(s) that claim foreign priority to or domestic benefit of the Patents, and iii) any patent application claiming foreign priority to or domestic benefit of the Patents and which covers solely Subsidiary Initial Know-How that was discovered, developed, generated, invented, conceived, and/or reduced to practice and solely related to the Initial Subsidiary Target of mtlDH1 as of the December 8, 2016 effective date of the Contribution Agreement by and among FTI, FTM2, and FTH. Also, this Confirmation of Patent Assignment pertains to any and all other rights, privileges, and advantages, including any and all rights to damages, profits, or recoveries of any nature for past infringement of the Patents, arising under or pursuant to any and all international agreements, treaties, or laws relating to the protection of industrial property, including all rights of priority under the International Convention for the Protection of Industrial Property, and in and to any such patent(s) as may issue thereon including any and all original and reissued patents which have been or shall be issued in the United States and foreign countries; said patent applications and patent(s) to be held and enjoyed by FTM2 for its own use and for each of its successors, assigns, and legal representatives, to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by FTI had FTI, FTM2, and FTH not entered into the Contribution Agreement.

**AND** for the same consideration, FTI hereby covenants and agrees to and with FTM2, their successors, legal representatives and assigns that FTI will, at the cost and expense of FTI, sign all papers

and documents, take all lawful oaths, and do all acts necessary or required to be done for the recordation of this Confirmation of Patent Assignment to FTM2.

**AND** FTI hereby requests the Director of the United States Patent and Trademark Office to issue any and all patents of the United States arising from such United States patents and patent applications included in the Patents to FTM2, its respective successors, legal representatives, and assigns.

[Remainder of Page Left Intentionally Blank]

IN WITNESS THEREOF, the parties hereto have caused this Confirmation of Patent Assignment to be executed on the date(s) indicated below.

Forma Therapeutics, Inc.

Forma Therapeutics Holdings, LLC

By: 

By: 

Name: Steven Tregay, Ph.D.

Name: Steven Tregay, Ph.D.

Title: President and CEO

Title: President and CEO

Date: NOVEMBER 6, 2018

Date: NOVEMBER 6, 2018

Forma TM2, Inc.

By: 

Name: Steven Tregay, Ph.D.

Title: CEO

Date: NOVEMBER 6, 2018

[Signature Page to Confirmation of Patent Assignment]

SCHEDULE A

Patents

Patent or Application No.	Country	Filing Date	Attorney Docket No.
62/053010	United States of America	19-Sep-2014	2012552-0056
9,815,817	United States of America	18-Sep-2015	2012552-0057
15/712446	United States of America	22-Sep-2017	2012552-0631
15/452256	United States of America	07-Mar-2017	2012552-0084
15/677748	United States of America	15-Aug-2017	2012552-0593
15/964812	United States of America	27-Apr-2018	2012552-0682
15/977512	United States of America	11-May-2018	2012552-0743
15/964844	United States of America	27-Apr-2018	2012552-0669
10,005,734	United States of America	18-Sep-2015	2012552-0067
9,771,349	United States of America	18-Sep-2015	2012552-0075
9,834,539	United States of America	18-Sep-2015	2012552-0083
62/053006	United States of America	19-Sep-2014	2012552-0064
62/128089	United States of America	04-Mar-2015	2012552-0065
62/150812	United States of America	21-Apr-2015	2012552-0082
62/150819	United States of America	21-Apr-2015	2012552-0074
62/206631	United States of America	18-Aug-2015	2012552-0066
62/150815	United States of America	21-Apr-2015	2012552-0122
9,624,175	United States of America	18-Sep-2015	2012552-0123
15/568051	United States of America	20-Oct-2017	2012552-0597
62/150816	United States of America	21-Apr-2015	2012552-0130
9,624,216	United States of America	18-Sep-2015	2012552-0131
15/568072	United States of America	20-Oct-2017	2012552-0598

[Remainder of Page Left Intentionally Blank]

8954702v1